低血圧性脳卒中の二次予防のためのナオキシントンカプセル:臨床的および臨床前の証拠のメタ分析

Liuding Wang¹, Yifan Chen¹, Ze Chang¹

¹Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.

Journal of ethnopharmacology

|September 5, 2025

まとめ

ナオキシントンは標準的な治療法と併用して再発性脳卒中のリスクを大幅に軽減します. この中華薬は二次性脳卒中予防に安全で有効で,出血のリスクは高まりません.

科学分野:

統合医療
心血管研究
薬理学について

背景:

低血圧性脳卒中は公衆衛生上の大きな課題であり,効果的な二次予防戦略が必要である.
伝統的な中国の特許薬であるナオキシントンは心血管疾患の管理に潜在性を示しています

研究の目的:

副次性脳卒中の予防のための補助療法としてのNaoxintongの有効性と安全性を評価する.
動脈硬化症の改善におけるナオキシントンのメカニズムを支持する臨床前研究の証拠をレビューする.

主な方法:

ランダム化制御試験 (RCT) と動物実験の体系的レビューとメタ解析
含有基準は,不全性脳卒中の再発と動脈硬化症に対するNaoxintongに焦点を当てた.
データ抽出,品質評価,メタ解析はReview Managerソフトウェアを使用して行われます.

主要な成果:

10件のRCTと8件の動物研究が分析に含まれていた.
標準治療と併用したナオキシントングは,1年および2年後に再発性不全性脳卒中のリスクを有意に低下させた (p < 0. 001).
血液出血や重篤な有害事象の増加は認められず,臨床前データは大動脈損傷の減少とプラークの安定性の改善を示唆した.

結論:

ナオキシントンは二次性脳卒中の予防に有効で安全です.
潜在的なメカニズムには,抗炎症効果,脂質代謝の調節,腸内微生物群の調節が含まれます.
再発性不全性脳卒中を予防するために,ナオキシントンの臨床使用を裏付ける証拠があります.

キーワード:

生物学的メカニズムグレード脳卒中の発生率中国伝統医学

さらに関連する動画

08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

692

04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.2K

関連する概念動画

01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:17

Ischemic Heart Disease: Overview

1.4K

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

1.4K

01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

671

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

671

関連する実験動画